FDA Finalises Rules for Companion Prescription Drug Apps

The Food and Drug Administration issued its final guidance governing software applications distributed by pharmaceutical companies alongside prescription drugs. The document draws a firm regulatory line between two types of digital tools: those that present standard dosing reminders or educational text, and those that actively calculate doses, interpret biometric feeds, or influence a clinical decision.

Under the finalised rules, software that ingests patient data to suggest drug adjustments or diagnose adverse events requires formal device clearance as Software as a Medical Device (SaMD), subjecting the code to rigorous post-market surveillance. Simple tracking logs and static symptom diaries remain classified as promotional or supplementary material, governed by drug marketing standards rather than device safety reviews.

Accountability Replaces Digital Add-Ons

Drug makers spent years attaching basic companion tools to high-margin therapies, collecting patient engagement metrics under loose consumer consent flows. The FDA's stance forces a structural split. If an app claims to predict a flare-up or modify an insulin ratio using machine learning, the sponsor must present validation trials equivalent to any clinical diagnostic hardware.

Examine the apps that accompany your prescriptions. Check the user agreement to see if the tool claims device status under FDA clearance or operates as marketing material, and decline data-sharing features that do not directly feed validated numbers back to your physician.